Stammdaten
Unternehmen
| Name | Entrada Therapeutics, Inc. |
|---|---|
| Ticker | TRDA |
| CIK | 0001689375 |
Branche
| SIC-Code | 2834 |
|---|---|
| Beschreibung | Pharmaceutical Preparations |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Titel | Entrada Therapeutics, Inc. |
Status
| Zuletzt geprüft | 2026-03-20 22:37:17.589698 |
|---|
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-10 | Dowden Nathan J | Officer, President & COO | Open Market Sale | -11,894 | 13.05 | -155,188.15 | -46,1% | |
| 2026-03-10 | WENTWORTH KORY JAMES | Officer, Chief Financial Officer | Open Market Sale | -11,388 | 13.02 | -148,215.96 | -44,0% | |
| 2026-03-09 | Dowden Nathan J | Officer, President & COO | Open Market Sale | -3,116 | 13.02 | -40,582.78 | -12,1% | |
| 2026-03-09 | WENTWORTH KORY JAMES | Officer, Chief Financial Officer | Open Market Sale | -5,089 | 13.00 | -66,162.60 | -19,6% | |
| 2026-03-04 | WENTWORTH KORY JAMES | Officer, Chief Financial Officer | Open Market Sale | -7,988 | 12.25 | -97,892.14 | -29,1% | |
| 2025-11-21 | WENTWORTH KORY JAMES | Officer, Chief Financial Officer | Open Market Sale | -8,910 | 9.98 | -88,931.60 | -26,4% | |
| 2025-11-14 | PARMAR KUSH | Director, 10% Owner | Open Market Sale | -200,000 | 8.80 | -1,760,000.00 | -522,7% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.